leisure time -WSS

leisure time

author：comprehensive 2025-09-06 02:13:01 - browse：3

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Dozens dead from Maui wildfires: What we know about the victims

WSS

Hospitals are dialing back on venture capital investing

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Physician assistants need a new name. Here's what it should be

Illumina slashes 2023 revenue projections yet again

Ascension's ugly legal battle over care for poor patients in Texas

JPM pitch from hospitals? Revenue streams outside of patient care

hotspot

leisure time

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Illinois Supreme Court finds assault weapons ban constitutional

How to save PrEP access — and even expand it

YouTube cracks down on misinformation on cancer treatment

Heart attack and stroke risk calculators need revising

Be careful with at

Duchenne breakthrough therapy leaves behind pioneering families

Biogen’s boardroom scandal saddles CEO with first crisis

The cancer drug shortage isn’t new — and neither are the solutions

Medicare Advantage overpayments discussion gets experts fired up

explore

STAT Virtual Event: JPM Recap, Live!

Stories you might have missed in 2023: health, science, medicine

Novo Nordisk touts Wegovy study, but still struggling with supply

Profiling embryos to choose those with higher IQs is almost a reality

Novo Nordisk touts Wegovy study, but still struggling with supply

Physician assistants need a new name. Here's what it should be

entertainment

hotspot

leisure time

explore